Cubital Tunnel Syndrome Market Research Report – Forecast till 2030

Cubital Tunnel Syndrome Market Research Report: By Cause (Injury, Noncancerous Fatty Tumor, Bone Tumor, Inflammation), Treatment (Diagnosis (MRI, X-Ray), Therapy (Non-Operative, Operative)), End User (Hospital, Retail Pharmacy) - Forecast Till 2030

ID: MRFR/Pharma/3210-HCR | December 2022 | Region: Global | 110 Pages         

Cubital Tunnel Syndrome Market Speak to Analyst Request a Free Sample

Cubital Tunnel Syndrome Market Scenario:


The cubital tunnel syndrome market is projected to reach USD 590.47 Million by 2030 at 7.10% CAGR during the forecast period 2022-2030.
Cubital tunnel syndrome is a condition of increased pressure on the ulnar nerve in the elbow. The ulnar nerve controls muscles and feeling in the hand. Furthermore, it can be caused by direct pressure, stretching, or decreased blood flow to the ulnar nerve. According to the WHO (2014), the incidence of carpal tunnel syndrome is >3 new cases per 1000 persons every year. Women are 3-4 times more susceptible than men. Increasing prevalence of the cubital tunnel syndrome is the major driving factor for the growth of the cubital tunnel syndrome market. Moreover, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, geriatric population is more likely to suffer from this disease; According to the Aging World in 2015, 562 million (or 8.0 %) were aged 65 and over across the globe, this has increased the prevalence of the diseases and contributed to the growth of the cubital tunnel syndrome market. However, lack of awareness among people and high cost of surgeries may restrain the growth of the cubital tunnel syndrome market.


Intended Audience



  • Biotechnological institutes

  • Pharmaceutical companies

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories 


Figure 1: cubital tunnel syndrome market share, by region (%) cubital tunnel syndrome market


Sources: WHO, annual reports, press release, white paper, and company presentation 


Segmentation


The cubital tunnel syndrome market is segmented on the basis of causes, treatment, and end users.


On the basis of causes, the cubital tunnel syndrome market is segmented into injury, noncancerous fatty tumors, bone tumors, inflammation, and others.


On the basis of treatment, the cubital tunnel syndrome market is segmented into diagnosis & therapy. The diagnosis is further segmented into nerve compression tests, X-ray, electrodiagnostic studies, MRI, and others. The therapy is further segmented into non-operative, and operative. The non-operative is further classified into NSAIDs and steroids. On the basis of end users, the market is segmented into hospital, retail pharmacy, and other. 


Regional Analysis


The Americas dominates the cubital tunnel syndrome market owing to large patient population. Additionally, increasing geriatric population, changing lifestyle, and increasing healthcare expenditure have boosted the growth of the cubital tunnel syndrome market in America. According to the Population Reference Bureau, the number of Americans ages 65 and over is projected to be more than double from 46 million in 2016 to over 98 million by 2060. Additionally, increasing awareness among the people regarding different monitoring procedures and well-developed technology has also contributed to the growth of the market.


Europe is the second largest cubital tunnel syndrome market, which is followed by Asia Pacific. Huge geriatric population, availability of funds for research, and government support for research & development projected to drive the cubital tunnel syndrome market in Europe.


Asia Pacific is the fastest growing region in the global market due to the presence of a increasing patient population, continuously developing economies, and increasing need for the better treatment. According to the WHO report published in 2015, Asia's elderly population is projected to reach nearly 923 million by 2050.


Whereas, the Middle East & Africa owns the least share of  the cubital tunnel syndrome market due to the presence of poor economy, especially, in Africa region. The market of this region is dominated by the Middle East due to well-developed healthcare sector and huge healthcare expenditure. 


Research Methodology


Cubital Tunnel Syndrome Market-


Sources: WHO, annual reports, press release, white paper, and company presentation 


Key players in cubital tunnel syndrome market


The major key players in the cubital tunnel syndrome market: Eli Lily and Company (US), GlaxoSmithKline PLC (UK), Pfizer Inc., Depomed Inc., Novartis International AG (Switzerland), Johnson & Johnson Services Inc. (US), Bristol-Myers Squibb and Company (US),  Sanofi S.A. (France), Debiopharm Group (Switzerland), Baxter Healthcare Corporation (US), Biogen Idec Inc. (US), Amneal Pharmaceuticals LLC. (US), Amgen, Inc. (US)



Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 590.47 Million
  CAGR   7.10% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Causes, Treatment, and End Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Eli Lily and Company (US), GlaxoSmithKline PLC (UK), Pfizer Inc., Depomed Inc., Novartis International AG (Switzerland), Johnson & Johnson Services Inc. (US), Bristol-Myers Squibb and Company (US), Sanofi S.A. (France), Debiopharm Group (Switzerland), Baxter Healthcare Corporation (US), Biogen Idec Inc. (US), Amneal Pharmaceuticals LLC. (US), Amgen, Inc. (US)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of the cubital tunnel syndrome
  • increasing healthcare expenditure
  • Strong encouragement from the government


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Cubital tunnel syndrome market CAGR would be 7.10% during the forecast period.

    Cubital tunnel syndrome market can find distraction in high cost of surgeries.

    The Americas would take the lead of the cubital tunnel syndrome market.

    End users included in the cubital tunnel syndrome market report are hospital, retail pharmacy, and other.

    The cubital tunnel syndrome market players are Amneal Pharmaceuticals LLC. (US), GlaxoSmithKline PLC (UK), Eli Lily and Company (US), Pfizer Inc., Depomed Inc., Johnson & Johnson Services Inc. (US), Novartis International AG (Switzerland), Debiopharm Group (Switzerland), Bristol-Myers Squibb and Company (US), Sanofi S.A. (France), Biogen Idec Inc. (US), Baxter Healthcare Corporation (US), Amgen, Inc. (US), and others.